Actively Recruiting
Study of How Patients With Multiple Myeloma Respond or Resist Teclistamab Treatment Using Single Immune Cell Analysis
Led by University Hospital, Toulouse · Updated on 2025-04-10
100
Participants Needed
18
Research Sites
8 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying patients with multiple myeloma to understand why some respond to teclistamab treatment while others do not. The study focuses on identifying immune and genetic features that differentiate responders from those who show primary resistance. It also examines changes linked to secondary resistance to teclistamab over time. Participants will have bone marrow samples collected at 12 weeks after starting teclistamab treatment, which is given in cycles of 28 days. The study involves analyzing these samples during the course of 18 treatment cycles to track the response and resistance mechanisms. Participants will be monitored with bone marrow sampling on day 1 of cycle 4 12 weeks into treatment. Researchers will assess the response to teclistamab at this time to understand how the disease reacts. The study is sponsored by University Hospital, Toulouse, and participation includes consenting adults diagnosed with multiple myeloma who are receiving teclistamab.
CONDITIONS
Brief Title
Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination
Research Team
H
Hervé AVET LOISEAU, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
